Tools to safely translate RNA LNP therapies to people
Official title: Advanced tools for translation of intravenously-infused RNA LNP therapeutics to the clinic
Funded at Rejuvenation Technologies, INC. · NIH-11602209 · Data updated 2026-11-12
A project to improve how intravenously given RNA LNP medicines can be used in patients by reducing immune reactions and making delivery safer.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Rejuvenation Technologies, INC. NIH-funded |
| Lab location | 1 site (Mountain View, UNITED STATES) |
| Project start | August 1, 2024 |
| Project end | May 31, 2027 |
| Funding year | 2026 |
| Award (this year) | $1,065,587 |
| NIH project number | 3R44TR005328-02S1 |
| Project ID | NIH-11602209 on NIH RePORTER |
Who could benefit from this research
✓Could help
Patients with liver or lung diseases who may benefit from regenerative therapies delivered via IV RNA LNPs could be eligible in future trials.
✕Less likely to help
People without qualifying liver or lung conditions or who cannot tolerate RNA LNP therapies may not benefit.
What this research studies
This project aims to develop better tools and methods to translate intravenously delivered RNA lipid nanoparticle therapies into clinical use. It focuses on preventing unwanted immune responses to the RNA and lipid components, which is essential for patient safety and treatment effectiveness. The team will test their approach using a telomere-extending biologic in mouse models of liver and lung disease to understand how to dose and deliver safely in humans. The work combines formulation science, preclinical testing, and translational study design to prepare for human trials.
Why it matters
Potential benefit: If successful, it could enable safer, more effective IV RNA therapies for liver and lung diseases and may slow progression by supporting regenerative strategies.
How similar studies have gone: Previous work on RNA LNPs has advanced vaccines, but IV-delivery is more challenging; this project aims to bridge that gap with translational-ready tools.
Where this research is happening
-
Rejuvenation Technologies, INC.
Mountain View, United States Active
Researchers
- Principal investigator: Ramunas, John — Rejuvenation Technologies, INC.
- Study coordinator: Ramunas, John
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.